Your Article Summary
A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression
Journal of Acquired Immune Deficiency Syndromes, 06/25/09
Martinez E et al. - In HIV-1-infected patients with virological suppression, abacavir/lamivudine did not meet the noninferiority outcome for treatment efficacy compared with tenofovir/emtricitabine.
Related Articles
Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Womens Interagency HIV Study
AIDS Patient Care and STDs, 11/19/09
Relevance Score: 95%
Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09
Relevance Score: 95%
HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09
Relevance Score: 95%
Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09
Relevance Score: 94%
Sperm May Play Leading Role In Spreading HIV
ScienceDaily, 10/27/09
Relevance Score: 94%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Clopidogrel Hypersensitivity: A Novel Multi-Day Outpatient Oral Desensitization Regimen
Annals of Pharmacotherapy, 12/16/09
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
Current Medical Research and Opinion, 12/14/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Association of trial registration with the results and conclusions of published trials of new oncology drugs
Trials, 12/17/09

See Latest Articles